I. Ayani

A cost-analysis of suspected adverse drug reactions in a hospital emergency ward

I. Ayani, C Aguirre, Garazi Gutiérrez et al. · Pharmacoepidemiology and Drug Safety · 1999 · 32 citations

Diagnosis, Hospital Emergency Ward, Emergency Care +18

Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)

Jordi Llaudó, Lourdes Anta, I. Ayani et al. · International Clinical Psychopharmacology · 2016 · 24 citations

Drug Safety, Therapeutic Drug Monitoring, Dose Administration +12

[Adverse drug reaction surveillance in pediatric and adult patients in an emergency room].

María José Muñoz, I. Ayani, J M Rodriguez-Sasiaín et al. · PubMed · 1998 · 22 citations

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

L. Anta Carabias, Jordi Llaudó, I. Ayani et al. · International Clinical Psychopharmacology · 2017 · 21 citations

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study

David P. Walling, Howard A Hassman, Lourdes Anta et al. · Drug Design Development and Therapy · 2021 · 16 citations · Full text